Operation Pangea XVIII: What the UK’s largest medicines seizure means for the Pharma Sector

The operation

Between 10 and 23 March 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) and UK Border Force, alongside INTERPOL and agencies across approximately 90 countries, seized over two million doses of illicit medicines at the UK border as part of Operation Pangea XVIII - the world’s largest coordinated initiative aimed at tackling the illegal medicines trade.

More than half of the seized medicines were controlled drugs, with the remainder classified as prescription-only medicines. The products most commonly intercepted were associated with sedation, pain relief, and erectile dysfunction treatments.

The MHRA’s Criminal Enforcement Unit took action to disrupt online supply routes, targeting websites, social media accounts and online marketplace listings. Andy Morling, Head of the MHRA’s Criminal Enforcement Unit, highlighted in a press release the scale of seizures in this year’s operation and highlighted the persistent demand for medicines outside the regulated supply chain, with criminal groups exploiting that demand and the serious risk that this poses to public health.

Balancing innovation with enforcement

It is worth placing this operation in the context of the MHRA’s broader direction of travel. The regulator has made clear that it is pursuing a strongly pro-innovation and pro-patient agenda: streamlining approvals, supporting clinical trial activity, and positioning the UK as a leading destination for life sciences investment. That progressive vision, however, goes hand in hand with robust enforcement against those who undermine the integrity of the medicines supply chain.

Operations like Pangea XVIII are a critical part of that picture. By targeting falsified and unlicensed medicines, the MHRA not only protects patients but also strengthens the legitimate pharmaceutical industry. When consumers and healthcare professionals can have confidence that medicines available in the UK meet strict standards for safety, quality, and effectiveness, it strengthens the entire regulated ecosystem - from innovators and manufacturers through to distributors and pharmacists.

Being tough on criminal operators is the other side of the coin to being supportive of lawful innovation.

What this means for pharma and life sciences businesses

For organisations operating in the pharmaceutical supply chain, Operation Pangea XVIII highlights critical priorities:

1. Supply chain compliance is non-negotiable. Businesses must ensure supply chains fully comply with UK regulatory requirements. This includes having robust systems for verifying the provenance of medicines and medical devices, maintaining appropriate licences and authorisations, and ensuring that distribution arrangements meet Good Distribution Practice (GDP) standards. Strong compliance protects patients and distinguishes legitimate operators from criminal actors who undermine public trust.
2. Digital channels are under increasing scrutiny. The MHRA’s enforcement activity is no longer confined to physical borders. The targeting of websites, social media accounts, and online marketplace listings signals a clear intent to police digital supply routes. Businesses involved in digital sales or marketing must ensure they are operating within the regulatory framework.
3. International cooperation is here to stay. With approximately 90 countries participating in Operation Pangea, this is a genuinely global enforcement effort. Businesses with cross-border supply chains should be alert to the fact that regulatory authorities are increasingly sharing intelligence and coordinating action.
4. Regulatory frameworks must keep pace. Over 15 years of Pangea operations, the UK has seized more than 25 million illicit medicines and medical devices valued at over £84 million. The scale and persistence of this threat means that regulatory and enforcement frameworks will continue to evolve, and businesses must stay ahead of those changes.

Hear more at the PING 2026 Conference

These issues sit at the heart of the regulatory landscape for the pharma and life sciences sector. We are delighted that Lawrence Tallon will be speaking at this year’s PING 2026 Conference (Pharmaceutical Industry Network Group), run by VWV in association with EMIG.

PING brings together people from right across the pharma ecosystem, from early-stage R&D through to finished product suppliers, distributors, wholesalers, and pharmacists, to explore the most pressing challenges facing the sector.

Find out more and register here.

How VWV can help

At VWV, our Pharmaceuticals and Life Sciences team supports businesses across the supply chain with regulatory compliance, supply chain integrity, commercial agreements and legal frameworks. Whether you need help ensuring your distribution arrangements are compliant, drafting or negotiating supply and distribution agreements, navigating MHRA inspections, reviewing authorisations, or understanding enforcement trends, we are here to assist. Our team combines extensive regulatory expertise with specialist commercial and contractual capability - we offer bespoke end to end support.

Read the full MHRA press release: Operation Pangea XVIII - GOV.UK

Read Medscape’s article: UK Tops Global Seizures in Illicit Medicine Crackdown

---

If you have any questions or concerns arising from this article, or if you would like to discuss how we can support your business, please contact Andrew Andrews or Greta Cicchetti.